AOD-9604 research has concentrated heavily on metabolic studies of this synthetic lipolytic domain of human growth hormone (Learn more), adipocyte biology, lipid metabolism and lipolysis-related pathways. Experimental studies have examined whether the C-terminal growth-hormone fragment can influence fat-cell metabolism without reproducing the full endocrine activity of intact growth hormone. Other laboratory work has explored cartilage and bone-related models, reflecting the broader biological interest in this hGH-derived fragment, alongside related metabolic research compounds such as 5-Amino-1MQ.
Built from the tail of growth hormone
Human growth hormone is a 191-amino-acid protein, and its final stretch has long interested metabolic researchers. AOD-9604 was developed in Melbourne in the late 1990s by Frank Ng and colleagues at Monash University working with Metabolic Pharmaceuticals, who patented it. The design takes hGH residues 177–191 and places a tyrosine at the front, where the native hormone carries a phenylalanine at position 176. That single substitution is why the peptide is often described as a modified 176–191 fragment rather than a plain one.
The fragment keeps a structural feature of the parent hormone: the two cysteines that correspond to positions 182 and 189 of hGH, which are joined by a disulfide bond in the intact protein and close a small loop in the peptide. At around 1.8 kDa, AOD-9604 is roughly a twelfth the size of the 22 kDa hormone, and it was designed to ask a focused question: could the fat-metabolism activity associated with this region be studied without the growth-promoting and glucose-raising effects of full-length growth hormone?
Zucker rats, obese mice and the β3-adrenergic question
The first published metabolic work, by Ng and colleagues in Hormone Research in 2000, used genetically obese Zucker rats. Over 19 days of treatment, the animals’ body-weight gain was less than half that of controls, and adipose tissue from treated rats showed increased lipolytic activity. Crucially for the design goal, euglycaemic clamp measurements showed no adverse effect on insulin sensitivity, in contrast to chronic treatment with intact hGH.
A 2001 study by Heffernan and colleagues in Endocrinology then asked how the effect worked. In obese mice, both hGH and AOD-9604 reduced body weight and body fat over 14 days and raised the depressed expression of the β3-adrenergic receptor, the main lipolytic receptor on fat cells, back towards lean-mouse levels. In β3-receptor knockout mice, the long-term weight change disappeared, yet a short experiment still showed increased energy expenditure and fat oxidation. The authors concluded that the receptor is involved but is not the direct route of action, which left the precise mechanism as an open research question.
Six clinical trials and an obesity programme that stopped
AOD-9604 is unusual among research peptides in having a substantial human trial record. Metabolic Pharmaceuticals ran six randomised, double-blind, placebo-controlled trials, testing safety first and then effect. The decisive test was a 24-week Phase 2b trial known as OPTIONS, which enrolled 536 people with obesity. Its weight-loss results were too small to reach statistical significance against placebo, and in February 2007 the company announced that the results did not support the commercial viability of AOD-9604 as an obesity treatment. Development for that indication ended there.
The programme still produced useful data. A pooled safety analysis by Stier, Vos and Kenley, published in 2013, reported a tolerability profile indistinguishable from placebo, no effect on serum IGF-1 and, unlike growth hormone, no adverse effect on oral glucose tolerance. For laboratory researchers, the absence of an IGF-1 response is the clearest human evidence that the fragment behaves differently from its parent hormone.
Cartilage repair in a rabbit knee model
After the obesity programme, interest shifted towards joint tissue. In a 2015 study in Annals of Clinical and Laboratory Science, Kwon and Park induced knee osteoarthritis in 32 New Zealand white rabbits with collagenase and compared four treatment groups placed directly in the joint: saline, hyaluronic acid, AOD-9604, and AOD-9604 combined with hyaluronic acid.
At eight weeks, all three treated groups had better gross and histological cartilage scores than the saline group, and the combination group scored better than either agent alone, with the shortest period of lameness. The authors interpreted this as enhanced cartilage regeneration in that model. It remains a single animal study, but it explains why AOD-9604 now appears in cartilage and connective-tissue research alongside its better-known metabolic history.
